The specific situation of the targeted drug Pralsetinib entering medical insurance in 2026

Pralsetinib (Pralsetinib) is a new type of targeted drug specifically used to treat cancer patients carrying RET gene rearrangement mutations. RET gene fusion mutations are considered to be driver mutations in various tumor types. Platinib blocks the proliferation and metastasis of tumor cells by inhibiting the activity of RET receptor tyrosine kinase. The drug has shown good clinical efficacy, especially for patients with RET mutation-positive non-small cell lung cancer (NSCLC) and medullary thyroid cancer (MTC). Platinib provides an innovative treatment option.

In China, the original drug Platinib has been launched and included in the medical insurance catalog. According to the latest medical insurance policy, the indications for platinib mainly include the following types of patients: first, adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for transfection rearrangement (RET) gene fusion; The second is for adult patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic treatment and pediatric patients aged 12 years and above; finally, it is suitable for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic treatment and are refractory to radioactive iodine.

The inclusion of platinib in medical insurance means that more patients who meet the indications can enjoy drug cost subsidies through the medical insurance system, which greatly reduces the financial burden on patients. The common packaging specifications of platinib are100mg 60 pills and 100mg 120 pills. The price per box is relatively expensive, but after being reimbursed by medical insurance, the out-of-pocket cost borne by the patient will be significantly reduced. This provides more therapeutic hope for patients in advanced stages of the disease, especially those cases where traditional treatments are ineffective.

However, because the drug price of platinib is still high, some patients may feel financial pressure, especially those on long-term treatment. So while insurance coverage has made drugs more available, affording the remaining out-of-pocket costs remains an important consideration for many patients.

Keyword tags: Pralsetinib, Pralsetinib, targeted drugs, RET gene, non-small cell lung cancer, medullary thyroid cancer, medical insurance reimbursement, drug price, indications

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto